Latest Period
Q1 2026
Security Snapshot
Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) Institutional Ownership
CUSIP: 45782T105
13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026
Institutions Reporting
82
Shares (Excl. Options)
5,376,678
Price
$1.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- INMB on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,376,678
- Total 13F value
- $6,085,619
- Portfolio coverage rank
- 0%
- Share change
- +306,342
- Value change
- +$301,036
- Number of holders
- 82
- Shares outstanding
- 27,969,231
- SEC-reported price per share
- $1.63
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- INMB - Inmune Bio, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 45782T105.
- 82 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 82 to 3 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $6,085,619 to $256,196.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 82 institutions filings for Q1 2026.
Security key
45782T105
Latest holder period
Q1 2026
13F holders
82
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
INMB full holder history
Inmune Bio, Inc. SEC filings
Inmune Bio, Inc. company facts
Inmune Bio, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45782T105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
INMB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 5.2% | $3,359,664 | 1,454,400 | Highbridge Capital Management, LLC | 30 Jun 2025 | |||
| CVI Investments, Inc. | 4.9% | -10% | $3,225,404 | -$239,596 | 1,396,279 | -6.9% | CVI Investments, Inc. | 30 Jun 2025 |
| Praetorian PR LLC | 3.4% | -54% | $2,127,972 | -$1,700,160 | 921,200 | -44% | Kupperman Harris | 30 Jun 2025 |
As of 31 Mar 2026, 82 institutional investors reported holding 5,376,678 shares of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB). This represents 19% of the company’s total 27,969,231 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
18%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4.3% | 1,194,112 | -1.5% | 0% | $1,349,347 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 687,015 | 0% | 0% | $776,327 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 494,969 | +12% | 0% | $559,464 |
| STATE STREET CORP | 1% | 290,879 | -16% | 0% | $328,693 |
| AQR CAPITAL MANAGEMENT LLC | 0.97% | 270,317 | +1217% | 0% | $305,458 |
| UBS Group AG | 0.91% | 253,340 | +317% | 0% | $286,274 |
| GOLDMAN SACHS GROUP INC | 0.83% | 231,586 | +310% | 0% | $261,692 |
| RAYMOND JAMES FINANCIAL INC | 0.73% | 203,245 | -3.5% | 0% | $229,667 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.7% | 194,391 | -23% | 0% | $219,662 |
| NORTHERN TRUST CORP | 0.66% | 184,225 | +4.9% | 0% | $208,174 |
| Dauntless Investment Group, LLC | 0.66% | 183,476 | -40% | 0.58% | $207,328 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.46% | 129,218 | 0% | 0% | $146,016 |
| VANGUARD FIDUCIARY TRUST CO | 0.44% | 123,184 | 0% | 0% | $139,198 |
| Westside Investment Management, Inc. | 0.39% | 108,300 | -0.6% | 0.02% | $122,383 |
| Bank of New York Mellon Corp | 0.19% | 53,628 | -8.4% | 0% | $60,599 |
| JANE STREET GROUP, LLC | 0.18% | 50,944 | +122% | 0% | $57,566 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 50,252 | 0% | 0% | $56,785 |
| Laird Norton Wetherby Trust Company, LLC | 0.18% | 50,000 | +11% | 0% | $56,500 |
| MORGAN STANLEY | 0.16% | 44,611 | -64% | 0% | $50,411 |
| Focus Partners Advisor Solutions, LLC | 0.15% | 43,025 | +4.7% | 0% | $48,618 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.14% | 40,120 | +6.1% | 0% | $45,336 |
| JPMORGAN CHASE & CO | 0.12% | 33,245 | -20% | 0% | $37,899 |
| Quadrature Capital Ltd | 0.12% | 32,362 | +91% | 0% | $36,569 |
| XTX Topco Ltd | 0.11% | 30,306 | -56% | 0% | $34,246 |
| BANK OF AMERICA CORP /DE/ | 0.09% | 25,502 | +38% | 0% | $28,818 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q1 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 11,084 | $256,196 | -$1,263 | $1.63 | 3 |
| 2026 Q1 | 5,376,678 | $6,085,619 | +$301,036 | $1.13 | 82 |
| 2025 Q4 | 5,083,649 | $7,930,848 | +$653,769 | $1.56 | 74 |
| 2025 Q3 | 4,655,922 | $9,636,676 | -$1,934,721 | $2.07 | 73 |
| 2025 Q2 | 5,623,690 | $12,725,267 | -$10,010,248 | $2.31 | 78 |
| 2025 Q1 | 6,162,475 | $48,114,521 | -$163,536 | $7.81 | 81 |
| 2024 Q4 | 6,324,914 | $29,538,643 | +$2,163,001 | $4.67 | 72 |
| 2024 Q3 | 5,352,153 | $28,834,750 | +$6,030,346 | $5.39 | 65 |
| 2024 Q2 | 4,566,933 | $40,279,815 | +$15,412,868 | $8.82 | 56 |
| 2024 Q1 | 2,738,821 | $32,179,382 | +$5,308,168 | $11.75 | 50 |
| 2023 Q4 | 2,292,004 | $25,807,938 | +$1,854,241 | $11.26 | 47 |
| 2023 Q3 | 2,133,529 | $14,477,326 | -$5,887,298 | $6.77 | 36 |
| 2023 Q2 | 2,186,070 | $24,850,986 | +$8,529,775 | $9.08 | 32 |
| 2023 Q1 | 1,804,387 | $11,657,371 | +$1,101,433 | $6.46 | 33 |
| 2022 Q4 | 1,645,407 | $10,430,707 | -$728,047 | $6.34 | 32 |
| 2022 Q3 | 1,912,551 | $11,855,780 | -$744,186 | $6.20 | 32 |
| 2022 Q2 | 2,010,894 | $17,633,536 | -$2,412,787 | $8.84 | 34 |
| 2022 Q1 | 2,294,234 | $19,315,368 | -$2,106,118 | $8.42 | 32 |
| 2021 Q4 | 2,484,556 | $25,343,080 | +$4,757,601 | $10.20 | 42 |
| 2021 Q3 | 1,942,445 | $37,703,608 | +$4,889,864 | $19.42 | 40 |
| 2021 Q2 | 1,710,752 | $30,053,028 | +$8,038,213 | $17.57 | 39 |
| 2021 Q1 | 1,305,763 | $15,492,692 | +$5,444,483 | $11.88 | 32 |
| 2020 Q4 | 793,136 | $13,655,776 | +$1,189,170 | $17.21 | 25 |
| 2020 Q3 | 992,741 | $10,252,248 | +$6,463,618 | $10.30 | 27 |
| 2020 Q2 | 358,561 | $1,881,000 | +$104,639 | $5.17 | 11 |